Western Financial Corp CA Buys 9,465 Shares of Boston Scientific Corporation $BSX

Key Points

• Western Financial Corp CA increased its stake in Boston Scientific Corporation by 116.4%, acquiring an additional 9,465 shares, bringing its total holdings to 17,597 shares valued at approximately $1.89 million.
• Boston Scientific's stock hit a 1-year low of $80.64 and a high of $109.50, with a market capitalization of $145.51 billion.
• In recent trading, analysts have boosted their price targets for Boston Scientific, with Raymond James Financial setting a new target of $124.00 and multiple analysts issuing "buy" ratings.

Western Financial Corp CA raised its holdings in shares of Boston Scientific Corporation (NYSE:BSX - Free Report) by 116.4% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 17,597 shares of the medical equipment provider's stock after purchasing an additional 9,465 shares during the quarter. Boston Scientific accounts for approximately 1.0% of Western Financial Corp CA's investment portfolio, making the stock its 28th largest holding. Western Financial Corp CA's holdings in Boston Scientific were worth $1,890,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also made changes to their positions in BSX. Brighton Jones LLC lifted its position in shares of Boston Scientific by 0.8% during the fourth quarter. Brighton Jones LLC now owns 27,376 shares of the medical equipment provider's stock worth $2,445,000 after purchasing an additional 226 shares during the last quarter. Ameriflex Group Inc. bought a new stake in shares of Boston Scientific during the fourth quarter worth $31,000. MassMutual Private Wealth & Trust FSB lifted its position in shares of Boston Scientific by 17.5% during the first quarter. MassMutual Private Wealth & Trust FSB now owns 6,325 shares of the medical equipment provider's stock worth $638,000 after purchasing an additional 940 shares during the last quarter. Versant Capital Management Inc lifted its position in shares of Boston Scientific by 134.9% during the first quarter. Versant Capital Management Inc now owns 5,435 shares of the medical equipment provider's stock worth $548,000 after purchasing an additional 3,121 shares during the last quarter. Finally, Central Pacific Bank Trust Division lifted its position in shares of Boston Scientific by 13.3% during the first quarter. Central Pacific Bank Trust Division now owns 30,501 shares of the medical equipment provider's stock worth $3,077,000 after purchasing an additional 3,575 shares during the last quarter. 89.07% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In other Boston Scientific news, Director Yoshiaki Fujimori sold 2,901 shares of Boston Scientific stock in a transaction dated Tuesday, July 29th. The stock was sold at an average price of $106.99, for a total value of $310,377.99. Following the transaction, the director owned 2,081 shares in the company, valued at $222,646.19. The trade was a 58.23% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Edward J. Ludwig sold 4,000 shares of Boston Scientific stock in a transaction dated Friday, July 25th. The shares were sold at an average price of $106.03, for a total value of $424,120.00. Following the completion of the transaction, the director owned 18,479 shares in the company, valued at $1,959,328.37. This trade represents a 17.79% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 174,214 shares of company stock worth $18,397,457 over the last ninety days. 0.50% of the stock is currently owned by company insiders.

Boston Scientific Stock Performance

BSX stock opened at $98.20 on Friday. The business has a 50-day moving average price of $103.79 and a 200 day moving average price of $102.07. Boston Scientific Corporation has a 1-year low of $80.64 and a 1-year high of $109.50. The company has a debt-to-equity ratio of 0.49, a current ratio of 1.37 and a quick ratio of 0.82. The company has a market capitalization of $145.51 billion, a P/E ratio of 58.45, a PEG ratio of 2.36 and a beta of 0.65.

Boston Scientific (NYSE:BSX - Get Free Report) last posted its earnings results on Wednesday, July 23rd. The medical equipment provider reported $0.75 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.72 by $0.03. Boston Scientific had a return on equity of 19.21% and a net margin of 13.55%.The company had revenue of $5.06 billion for the quarter, compared to analyst estimates of $4.89 billion. During the same quarter in the previous year, the firm earned $0.62 earnings per share. The firm's quarterly revenue was up 22.8% compared to the same quarter last year. Boston Scientific has set its Q3 2025 guidance at 0.700-0.720 EPS. As a group, equities research analysts forecast that Boston Scientific Corporation will post 2.85 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several analysts have recently weighed in on the company. Raymond James Financial lifted their target price on Boston Scientific from $121.00 to $124.00 and gave the stock a "strong-buy" rating in a research report on Thursday, July 24th. Needham & Company LLC restated a "buy" rating and issued a $121.00 price objective on shares of Boston Scientific in a report on Friday, September 19th. Wells Fargo & Company lifted their price objective on Boston Scientific from $118.00 to $124.00 and gave the company an "overweight" rating in a report on Thursday, July 24th. Royal Bank Of Canada restated an "outperform" rating on shares of Boston Scientific in a report on Thursday, July 24th. Finally, Oppenheimer upgraded Boston Scientific from a "market perform" rating to an "outperform" rating and lifted their price objective for the company from $118.00 to $125.00 in a report on Monday, September 8th. Three investment analysts have rated the stock with a Strong Buy rating, twenty-two have issued a Buy rating and one has given a Hold rating to the stock. According to data from MarketBeat, the company currently has an average rating of "Buy" and a consensus target price of $118.17.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.

Want to see what other hedge funds are holding BSX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Boston Scientific Corporation (NYSE:BSX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.